Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 6/20 | 0.53 |
| ▸ | LRRK2 | Q5S007 | 3/20 | 0.43 |
| ▸ | DYRK1A | Q13627 | 5/20 | 0.42 |
| ▸ | SCN5A | Q14524 | 3/20 | 0.40 |
| ▸ | FYN | P06241 | 1/20 | 0.37 |
| ▸ | TSHR | P16473 | 1/20 | 0.36 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.36 |
| ▸ | BRD4 | O60885 | 1/20 | 0.34 |
| ▸ | CLK2 | P49760 | 1/20 | 0.34 |
| ▸ | HASPIN | Q8TF76 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26539001 | 0.93 | CYP1A2 (0.52) | CYP1A2LRRK2DYRK1ASCN5AFYN | |
| SCHEMBL20203834 | 0.89 | CYP1A2 (0.68) | CYP1A2LRRK2DYRK1ASCN5AFYN | |
| SCHEMBL20203733 | 0.81 | CYP1A2 (0.78) | CYP1A2LRRK2DYRK1ASCN5ACLK2 | |
| SCHEMBL20203858 | 0.79 | CYP1A2 (0.65) | CYP1A2DYRK1ASCN5AFYN | |
| SCHEMBL26538938 | 0.79 | CYP1A2 (0.54) | CYP1A2DYRK1ASCN5AFYNTSHR | |
| SCHEMBL20203883 | 0.78 | CYP1A2 (0.53) | CYP1A2DYRK1ASCN5AFYNTSHR | |
| SCHEMBL20203912 | 0.78 | CYP1A2 (0.55) | CYP1A2DYRK1ASCN5AFYNTSHR | |
| SCHEMBL20203742 | 0.78 | CYP1A2 (0.77) | CYP1A2DYRK1ASCN5AFYNTSHR | |
| SCHEMBL26538995 | 0.76 | CYP1A2 (0.74) | CYP1A2LRRK2DYRK1ASCN5ACLK2 | |
| SCHEMBL20203885 | 0.75 | CYP1A2 (0.46) | CYP1A2DYRK1ASCN5AFYNBRD4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230322790-A1 | COMPOUNDS AND THEIR METHODS OF USE | PRAXIS PRECISION MEDICINES, INC. | 2023-10-12 | — | — | US | disclosed |
| US-20230322790-A1 | COMPOUNDS AND THEIR METHODS OF USE | PRAXIS PRECISION MEDICINES, INC. | 2023-10-12 | — | — | US | disclosed |
| US-20210188852-A1 | COMPOUNDS AND THEIR METHODS OF USE | PRAXIS PRECISION MEDICINES, INC. | 2021-06-24 | — | — | US | disclosed |
| WO-2018098499-A1 | COMPOUNDS AND THEIR METHODS OF USE | PRAXIS PRECISION MEDICINES, INC. (US) | 2018-05-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210188852-A1 | COMPOUNDS AND THEIR METHODS OF USE | SCN1A, SCN3A, SCN1B | CYP1A2 1988/4885LRRK2 2693/4885DYRK1A 4493/4885 |
| US-20230322790-A1 | COMPOUNDS AND THEIR METHODS OF USE | SCN1A, SCN3A, SCN1B | CYP1A2 1988/4885LRRK2 2693/4885DYRK1A 4493/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.